Overview
IKT market data
Price History
IKT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.16 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.91 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -5,981.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.33 – $2.53 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $336.3M · P/B 1.44 · P/S 1,050.88.
Company News
Inhibikase Therapeutics Q2 EPS $(0.11), InlineBenzinga · Aug 11, 2026, 8:16 PM
8-K filing — Inhibikase Therapeutics, Inc. (IKT)SEC EDGAR · Jul 23, 2026, 12:32 PM
Inhibikase Therapeutics Says FDA Grants Orphan Drug Designation To Its Lead Product Candidate IKT-001, Prodrug Of Imatinib Mesylate, For Treatment Of PAHBenzinga · Jul 23, 2026, 12:03 PM
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market SessionBenzinga · Jul 21, 2026, 12:01 PM
Inhibikase Therapeutics shares are trading higher after the company announced that it has sold 25,000,000 shares of the company’s common stock to RA Capital Management through its at-the-market facility for gross proceeds of $50 million.Benzinga · Jul 14, 2026, 3:01 PM
Inhibikase Therapeutics Sells 25M Common Shares To RA Capital Management Through At-The-Market Facility For Gross Proceeds Of $50MBenzinga · Jul 14, 2026, 12:06 PM
Oppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Target of $5Benzinga · Jun 10, 2026, 6:05 PM
Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightGlobenewswire Inc · May 19, 2026, 5:15 PM